Embecta (EMBC) Q2 2025 earnings summary

Executive summary

• Q2 FY2025 revenue was $259 million, down 9.8% year-over-year, but exceeded expectations due to operational efficiency and less FX headwind; adjusted constant currency revenue fell 7.7%.

• Net income for Q2 was $23.5 million ($0.40 per share), down from $28.9 million ($0.50) last year; adjusted net income rose to $40.7 million ($0.70 per share).

• Strategic initiatives included brand transition progress in the U.S. and Canada, new pen needle co-packaging orders with generic GLP-1 drugs, and restructuring to streamline operations.

• Discontinued the insulin patch pump program and completed most separation activities, with restructuring plans to optimize cash flow and focus on core business.

• Achieved Great Place to Work certification in multiple countries and published updated FITR/FITTER recommendations.

Financial highlights

• Q2 gross profit was $164.1 million (63.4% margin), down from $185.4 million (64.6%) year-over-year; adjusted gross profit was $165.6 million (63.7%).

• Adjusted operating income was $81.4 million (31.4% margin), up from $74.9 million (26.1%) year-over-year.

• Adjusted EBITDA for Q2 was $97.1 million (37.5% margin), up from $90.8 million (31.6%).

• Six-month revenue was $520.9 million, down 7.7% year-over-year; adjusted EBITDA for six months was $194.4 million (37.3% margin).

• Dividend of $0.15 per share declared.

Outlook and guidance

• FY2025 reported revenue guidance narrowed to $1,073–$1,090 million, with reported revenue decline of 4.4% to 2.9%; adjusted constant currency revenue expected to decline 4.0% to 2.5%.

• Adjusted gross margin guidance lowered to 62.75–63.75% due to tariffs and lower revenue.

• Adjusted operating margin guidance raised to 29.75–30.75% and adjusted EBITDA margin to 36.25–37.25%.

• Adjusted EPS guidance maintained at $2.70–$2.90.

• Restructuring actions expected to be substantially completed by fiscal year-end, with cumulative pretax costs for the patch pump plan estimated at $30–$40 million and for the 2025 plan at $4–$5 million.